XML 55 R44.htm IDEA: XBRL DOCUMENT
v3.23.3

Investments in Non-Marketable Securities - Narrative (Details) - USD ($) | 1 Months Ended | 3 Months Ended | 9 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | ---
Mar. 31, 2023 | Sep. 30, 2021 | Apr. 30, 2021 | Jun. 30, 2020 | Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2022 | Jun. 30, 2022 | Mar. 31, 2022
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Payments to acquire other investments |  |  |  |  |  |  | $ 1,191,000 | $ 5,300,000 |  |  |
Total non-marketable equity securities |  |  |  |  | $ 18,013,000 |  | 18,013,000 |  | $ 20,510,000 |  |
Total revenues |  |  |  |  | 9,277,000 | $ 34,470,000 | 43,582,000 | 108,215,000 |  |  |
Impairment of investment in non-marketable equity securities |  |  |  |  | 3,900,000 |  | 3,875,000 | 0 |  |  |
Unrealized or realized gains or losses |  |  |  |  | 0 | 0 | 0 | 0 |  |  |
Research and development revenue |  |  |  |  |  |  |  |  |  |  |
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  | 3,882,000 | 6,428,000 | 18,775,000 | $ 14,839,000 |  |  |
seqWell | Research and development revenue |  |  |  |  |  |  |  |  |  |  |
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total revenues |  |  |  |  | $ 69,000 |  | $ 187,000 |  |  |  |
Common Stock | seqWell |  |  |  |  |  |  |  |  |  |  |
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Shares issued in exchange for service |  |  |  |  | 65,982 |  | 179,897 |  |  |  |
seqWell |  |  |  |  |  |  |  |  |  |  |
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Non-marketable equity securities purchased (in shares) |  |  |  |  |  |  |  |  |  |  | 1,000,000
Total non-marketable equity securities |  |  |  |  | $ 2,598,000 |  | $ 2,598,000 |  | 5,000,000 |  | $ 5,000,000
Impairment of investment in non-marketable equity securities |  |  |  |  | 3,000,000 |  |  |  |  |  |
Arzeda |  |  |  |  |  |  |  |  |  |  |
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total non-marketable equity securities |  |  |  |  | 444,000 |  | $ 444,000 |  | $ 1,289,000 |  |
Impairment of investment in non-marketable equity securities |  |  |  |  | $ 900,000 |  |  |  |  |  |
Series A Preferred Stock | MAI | MCRA |  |  |  |  |  |  |  |  |  |  |
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of shares received in exchange for services (in shares) |  |  |  |  |  |  | 19,277,914 |  |  |  |
Series C-1 Preferred Stock | seqWell |  |  |  |  |  |  |  |  |  |  |
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Non-marketable equity securities purchased (in shares) |  |  |  |  | 88,256 |  | 88,256 |  |  |  |
Series B-2 Preferred Stock | Arzeda |  |  |  |  |  |  |  |  |  |  |
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Non-marketable equity securities purchased (in shares) |  |  |  |  | 207,070 |  | 207,070 |  |  |  |
Common Stock Warrants | seqWell |  |  |  |  |  |  |  |  |  |  |
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Non-marketable equity securities purchased (in shares) |  |  |  |  | 44,128 |  | 44,128 |  |  |  |
Total non-marketable equity securities |  |  |  |  | $ 400,000 |  | $ 400,000 |  |  |  |
MAI |  |  |  |  |  |  |  |  |  |  |
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Unrealized gain on non-marketable securities |  |  |  |  |  | $ 200,000 |  |  |  |  |
MAI | Series B Preferred Stock |  |  |  |  |  |  |  |  |  |  |
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of shares purchased (in shares) | 985,545 | 9,198,423 |  |  |  |  |  |  |  | 1,587,049 |
Payments to acquire other investments | $ 800,000 | $ 7,000,000 |  |  |  |  |  |  |  |  |
MAI | Series A Preferred Stock |  |  |  |  |  |  |  |  |  |  |
Marketable Securities [Line Items] |  |  |  |  |  |  |  |  |  |  |
Number of shares purchased (in shares) |  |  | 1,000,000 | 1,587,050 |  |  |  |  |  |  |
Payments to acquire other investments |  |  | $ 600,000 | $ 1,000,000 |  |  |  |  |  |  |

X
- Definition Equity Securities Without Readily Determinable Fair Value, Shares + References No definition available. + Details
Name: | cdxs_EquitySecuritiesWithoutReadilyDeterminableFairValueShares
Namespace Prefix: | cdxs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Non Marketable Debt Securities Without Readily Determinable Fair Value Annual Amount + References No definition available. + Details
Name: | cdxs_NonMarketableDebtSecuritiesWithoutReadilyDeterminableFairValueAnnualAmount
Namespace Prefix: | cdxs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of impairment loss on investment in equity security without readily determinable fair value. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3 + Details
Name: | us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Number of shares of investment owned. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-6 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480493/946-210-55-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480524/946-210-50-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.12-12(Column B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-12B(Column B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 6 -Subparagraph (SX 210.12-14(Column B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6 + Details
Name: | us-gaap_InvestmentOwnedBalanceShares
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_MarketableSecuritiesLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The number of shares issued as [noncash or part noncash] consideration for a business or asset acquired. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details
Name: | us-gaap_NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationSharesIssued1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of cash outflow to acquire investments classified as other. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details
Name: | us-gaap_PaymentsToAcquireOtherInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders. + References No definition available. + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesIssuedForServices
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of unrealized gain (loss) on investment. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details
Name: | us-gaap_UnrealizedGainLossOnInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_ProductOrServiceAxis=cdxs_ResearchandDevelopmentRevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=cdxs_SeqWellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SecurityOwnedNotReadilyMarketableAxis=cdxs_SeqWellMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SecurityOwnedNotReadilyMarketableAxis=cdxs_ArzedaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdxs_MolecularAssembliesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=cdxs_MasterCollaborationResearchAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=cdxs_SeriesC1PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=cdxs_SeriesB2PreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=cdxs_CommonStockWarrantsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=cdxs_MolecularAssembliesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |